A Phase III Randomized Multicenter Open-Label Study of IDRX-42 versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors GIST after Imatinib Therapy StrateGIST 3

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT07218926

Study #:
STUDY00162107

Start Date:
Mar 27, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT07218926

View Complete Trial Details & Eligibility at ClinicalTrials.gov